Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
The Lancet. HIV|November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE studyMark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
Frontiers in Immunology|July 19, 2023
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccinationNicole L Messina, Mariana G Sperotto, Marco A M Puga, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
BMC Medical Research Methodology|February 21, 2022
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trialRebecca M Turner, Anna Turkova, Cecilia L Moore, et al.
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Eclinicalmedicine|September 18, 2023
Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trialLaure F Pittet, Cecilia L Moore, Ellie McDonald, et al.
The New England Journal of Medicine|April 26, 2023
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care WorkersLaure F Pittet, Nicole L Messina, Francesca Orsini, et al.
Pageof 2